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A B S T R A C T
Background
COVID-19 infection poses a serious risk to patients and – due to its contagious nature – to those healthcare workers (HCWs) treating them.
If the mouth and nose of HCWs are irrigated with antimicrobial solutions, this may help reduce the risk of active infection being passed
from infected patients to HCWs through droplet transmission or direct contact. However, the use of such antimicrobial solutions may be
associated with harms related to the toxicity of the solutions themselves, or alterations in the natural microbial flora of the mouth or nose.
Understanding these possible side eFects is particularly important when the HCWs are otherwise fit and well.
Objectives
To assess the benefits and harms of antimicrobial mouthwashes and nasal sprays used by healthcare workers (HCWs) to protect themselves
when treating patients with suspected or confirmed COVID-19 infection.
Search methods
Information Specialists from Cochrane ENT and Cochrane Oral Health searched the Central Register of Controlled Trials (CENTRAL 2020,
Issue 6); Ovid MEDLINE; Ovid Embase and additional sources for published and unpublished trials. The date of the search was 1 June 2020.
Selection criteria
This is a question that urgently requires evidence, however at the present time we did not anticipate finding many completed randomised
controlled trials (RCTs). We therefore planned to include the following types of studies: RCTs; quasi-RCTs; non-randomised controlled
trials; prospective cohort studies;  retrospective cohort studies;  cross-sectional studies;  controlled before-and-aKer studies. We set no
minimum duration for the studies. 
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We sought studies comparing any antimicrobial mouthwash and/or nasal spray (alone or in combination) at any concentration, delivered
to HCWs, with or without the same intervention being given to the patients with COVID-19.
Data collection and analysis
We used standard Cochrane methodological procedures. Our primary outcomes were: 1) incidence of symptomatic or test-positive
COVID-19 infection in HCWs; 2) significant adverse event: anosmia (or disturbance in sense of smell). Our secondary outcomes were: 3) viral
content of aerosol, when present (if intervention administered to patients); 4) other adverse events: changes in microbiome in oral cavity,
nasal cavity, oro- or nasopharynx; 5) other adverse events: allergy, irritation/burning of nasal, oral or oropharyngeal mucosa (e.g. erosions,
ulcers, bleeding), long-term staining of mucous membranes or teeth, accidental ingestion. We planned to use GRADE to assess the certainty
of the evidence for each outcome.
Main results
We found no completed studies to include in this review. We identified three ongoing studies (including two RCTs), which aim to enrol
nearly 700 participants. The interventions included in these trials are povidone iodine, nitric oxide and GLS-1200 oral spray (the constituent
of this spray is unclear and may not be antimicrobial in nature). 
Authors' conclusions
We identified no studies for inclusion in this review. This is not surprising given the relatively recent emergence of COVID-19 infection. It
is promising that the question posed in this review is being addressed by two RCTs and a non-randomised study. We are concerned that
only one of the ongoing studies specifically states that it will evaluate adverse events and it is not clear if this will include changes in the
sense of smell or to the oral and nasal microbiota, and any consequences thereof.
Very few interventions have large and dramatic eFect sizes. If a positive treatment eFect is demonstrated when studies are available for
inclusion in this review, it may not be large. In these circumstances in particular, where those receiving the intervention are otherwise fit
and well, it may be a challenge to weigh up the benefits against the harms if the latter are of uncertain frequency and severity.
P L A I N   L A N G U A G E   S U M M A R Y
What are the benefits and risks of healthcare workers using antimicrobial mouthwashes or nasal sprays to protect themselves when
they treat people with COVID-19?
Why is this question important?
COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with COVID-19 develop a mild to moderate
respiratory illness, and some may have no symptoms (asymptomatic infection). Others experience severe symptoms and need specialist
treatment and intensive care.
COVID-19 spreads from person to person primarily through droplets that are produced when an infected person coughs, sneezes or talks.
A person can also become infected by touching a surface or object that has viral droplets on it, and then touching their own mouth or nose.
Healthcare workers who treat people with COVID-19 are at risk of becoming infected themselves. Self-administered use of an antimicrobial
mouthwash (to rinse the mouth) or nasal spray (sprayed into the nose) might help healthcare workers to protect themselves against
infection. Antimicrobial mouthwashes and nasal sprays are liquids that kill or stop the growth of micro-organisms such as viruses or
bacteria.
As with any medical treatment, antimicrobial mouthwashes and nasal sprays have potential risks as well as benefits. It is possible that
using mouthwashes or nasal sprays could cause a variety of unwanted (adverse) eFects, including irritation, allergic reactions or loss of
smell. They may also remove micro-organisms from the mouth or nose that are useful for protecting the body against infection.
To assess the benefits and risks of self-administered antimicrobial mouthwashes and nasal sprays for healthcare workers treating patients
with COVID-19, we set out to review the research evidence.
How did we search for evidence?
Our team of researchers searched the medical literature for studies that compared the eFects of any antimicrobial mouthwash or nasal
spray used by healthcare workers against no treatment, water or a salt solution.
What did we find?
We found no completed studies to include in this review.
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We found three studies currently in progress that aim to enrol nearly 700 participants. These studies are investigating the eFects of
povidone iodine (as a mouthwash and nasal spray), nitric oxide (as a mouthwash and nasal spray) and GLS-1200 nasal spray (though the
content of this spray is unclear, and it may not turn out to include an antimicrobial agent).
Two of the studies are randomised controlled trials (clinical, real-life studies where people are randomly put into one of two or more
treatment groups). This type of study provides the most robust evidence about the eFects of a treatment. The third study is a non-
randomised clinical study.
Only one of the ongoing studies specifically states that it will investigate adverse events. It is not clear whether this will include changes in
the sense of smell or to the mix of micro-organisms that are present in the mouth or nose, and the consequences of these changes.
What does this mean?
There is currently no evidence relating to the benefits and risks of healthcare workers' use of antimicrobial mouthwashes or nasal sprays
to protect themselves when they treat people with COVID-19.
Two randomised controlled trials and one non-randomised study are underway. Once these studies are completed, we will be able to
analyse them and include their findings in an updated version of this review.
It is important that future studies collect and analyse information about adverse events. Only one of the ongoing studies we identified
specifically states that it will investigate these. If future studies show a beneficial eFect of mouthwashes and nasal sprays, it may not be
a large eFect (very few health interventions have large and dramatic eFect sizes). It will only be possible to weigh up potentially small
benefits against risks if any adverse events that occur are reported in studies.
How-up-to date is this review?
We last searched for evidence on 1 June 2020. This review covered research that was available up to that date, but did not consider any
evidence that may have been produced since then.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Nasal sprays and gargles compared to no intervention for protecting healthcare workers when treating patients with
suspected COVID-19
Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infec-
tion
Patient or population: healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection
Setting: any healthcare setting
Intervention: any antimicrobial mouthwash and/or nasal spray
Comparison: no treatment or saline or water
Anticipated absolute effects* (95% CI)Outcomes Relative ef-
fect










Incidence of symptomatic or test-positive COVID-19 in-
fection in HCWs
No data available (no included studies)
Anosmia No data available (no included studies)
Viral content of aerosol No data available (no included studies)
Changes in microbiome in oral cavity, nasal cavity oro-
or nasopharynx
No data available (no included studies)
Other adverse events No data available (no included studies)
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RR: risk ratio; OR: odds ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect




































































Cochrane Database of Systematic Reviews
B A C K G R O U N D
Description of the condition
The emergence of a novel coronavirus (SARS-CoV-2) in late 2019 has
resulted in a global pandemic of an infectious condition - COVID-19.
To date, almost 19.9 million people have been reported to be
infected, with over 732,000 deaths. Patients may be asymptomatic,
or they may have an illness with symptoms varying from mild
to very severe. Not all those who have the condition are tested
for the presence of the virus. Multiple therapeutic interventions
and vaccines are in development. The steroid dexamethasone
has been shown to reduce the mortality rate of people requiring
invasive ventilation for COVID-19 by a third (Horby 2020), and
the antiviral drug remdesivir can reduce the time to recovery of
patients in hospital (Beigel 2020). Prevention eForts have focused
on measures of social distancing and isolation in many countries.
Healthcare workers are at the forefront of this crisis, with repeated
exposure to individuals who are, or may be, infected, and are
therefore at risk themselves. Access to and proper use of personal
protective equipment (PPE) is a key intervention that should
reduce the frequency of transmission of the infection to healthcare
workers.
These workers may be especially at risk when undertaking 'aerosol-
generating procedures' (AGPs). This is any medical, dental or
patient-care procedure that results in the production of airborne
particles (aerosols) from the upper aerodigestive tract (mouth,
nose, throat, oesophagus) and lower respiratory tract where the
virus is shedding. These can remain suspended in the air and travel
over a distance. They may cause infection if they are inhaled. Such
procedures therefore create the potential for airborne transmission
of infection.
This review is one of a set of three which consider two measures
that may protect healthcare workers and patients - both for their
own benefit, and to reduce the frequency of onward transmission.
These two measures are 1) the pre-procedural use of mouthwashes
and nasal sprays by patients, to reduce the risk that any aerosol
that they generate will infect healthcare workers, and 2) the use
of mouthwashes and nasal sprays by healthcare workers pre- and
post-exposure to patients with confirmed or suspected infection
to reduce the risk of acquiring such infection through their mouth
or nose. This particular review focuses on the protection of HCWs
treating patients with suspected or confirmed COVID-19 infection. It
evaluates the use of mouthwashes and nasal sprays by those HCWs
(2) above) with or without the addition of similar interventions
by the patients (1) above). (The other two reviews will focus on
a) the use of antimicrobial mouthwashes and nasal sprays in
the treatment of patients with suspected or confirmed COVID-19
infection (Burton 2020a) and b) the protection of HCWs when they
are undertaking AGPs on patients who are not known to have, or
suspected of having, COVID-19 infection (Burton 2020b)).
Description of the intervention
Mouthwashes are oral rinsing solutions: many are in common
use to manage halitosis, prevent tooth decay and reduce plaque
formation. In some countries they are recommended as a
hygiene measure during the regular cold and flu season. Many
mouthwashes with some antimicrobial activity can be purchased
over the counter, and others are available on prescription. The
antimicrobial agents and eFectiveness vary and whilst most have
some antibacterial properties a few are also antiviral.
Similar topical antimicrobial solutions may be administered via
the nose using a nasal spray, or by direct irrigation or douching
(administered by sniFing a solution through each nostril and
spitting it out).
How the intervention might work
There has been considerable interest in the use of nasal irrigation
or oral rinses to prevent transmission of upper respiratory tract
infections (URTI) caused by viruses, or to alleviate their symptoms.
Transmission of such disease occurs by the inhalation of small
droplets containing viral particles, or by transfer (for example,
from surfaces to hands, and then to the face, mouth and nose).
Rinsing the mouth and/or nose may eradicate viral particles
completely - preventing transmission to that individual - or reduce
the viral load that the individual is exposed to. This may prevent
the disease developing in that individual or reduce the severity
of it. Gargles that have been investigated for their ability to
reduce viral transmission, include tea (or components of tea) (Ide
2016), water (Goodall 2014) and povidone iodine (Kitamura 2007;
Satomura 2005). Other mouthwashes in common use, including
hydrogen peroxide and chlorhexidine, may also have antiviral
activity (Bernstein 1990).
Nasal irrigation with topical antimicrobial solutions similar to those
used as mouthwashes has also been investigated. Carrageenan, a
carbohydrate found in red seaweed, has been trialled as an antiviral
nasal spray. Studies have identified a decrease in the nasal viral
load from URTI, but results on symptomatic improvement have
been mixed (Eccles 2010; Eccles 2015; Fazekas 2012; Ludwig 2013).
Given the new emergence of COVID-19, the eFicacy of nasal or oral
irrigation fluids against this disease is not yet known. However,
activity against similar novel coronaviruses (such as those
responsible for severe acute respiratory syndrome (SARS) and
Middle East respiratory syndrome (MERS)) has been demonstrated
for some preparations (Eggers 2015; Kariwa 2006). Gargle solutions
of povidone iodine have been shown to be active against the
coronaviruses causing both MERS and SARS in vitro (Eggers 2018;
Kariwa 2006).
How the intervention might cause harm
Use of mouthwash or nasal irrigation has the potential to cause a
variety of adverse eFects. In common with many treatments, there
is the possibility of irritation or allergic reaction to components of
the product. A key concern for any agent used intranasally is the
potential for long-term damage resulting in anosmia (loss of sense
of smell). However, anosmia may also be a symptom of COVID-19
infection.
There is also a concern that local application of antimicrobials
will disrupt the normal nasal and oral microbiota. The microbiome
is increasingly recognised as playing a vital role in preventing
colonisation with invading pathogens, supporting the host immune
system and a variety of other functions (Kilian 2016; Man
2017). Alteration of this delicate environment by exposure to
antimicrobial compounds could alter the composition and/or
activities  of the oral and nasal microbiotas. This may occur
through reduced total microbial abundance and/or via the selective
suppression of commensal micro-organisms with the greatest
Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with
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susceptibility to the treatment. Potential health problems resulting
from this include an increased risk of infection due to the
suppression of colonisation resistance, by which commensal
micro-organisms inhibit extrinsic pathogens; the overgrowth of
species within the microbiota with pathogenic potential, and
interference with beneficial host-microbe interactions that prime
the immune system.
Other potential harms are related to specific irrigation fluids. These
include the risk of excess iodine ingestion from iodine-containing
gargle solution or staining of teeth with chlorhexidine.
O B J E C T I V E S
To assess the benefits and harms of antimicrobial mouthwashes
and nasal sprays used by healthcare workers (HCWs) to protect
themselves when treating patients with suspected or confirmed
COVID-19 infection.
The review also sought to address whether there is a diFerence if
the intervention is used solely by the HCWs or both the HCWs and
the patients they are caring for.
M E T H O D S
Criteria for considering studies for this review
Types of studies
This is a question that urgently requires evidence, however at the
present time we did not anticipate finding many completed RCTs.
We therefore included the following types of studies:
• randomised controlled trials (RCTs);
• quasi-RCTs;
• non-randomised controlled trials;
• prospective cohort studies;
• retrospective cohort studies;
• cross-sectional studies;
• controlled before-and-aKer studies.
There was no minimum duration for the studies.
Types of participants






Any antimicrobial mouthwash and/or nasal spray (alone or in
combination) at any concentration, delivered with any frequency or
dosage to the HCWs, with or without the same intervention being
given to the COVID-19 patients.
Comparator
No treatment or saline or water.
Types of outcome measures
We analysed the following outcomes in the review, but we did not
use them as a basis for including or excluding studies.
We assessed the primary outcomes at a minimum of two weeks. For
all other outcomes, there was no minimum follow-up.
For all outcomes we planned to accept the method of measurement
used by the trialists but we would take a critical approach to the
value of each measure.
Primary outcomes
• Incidence of symptomatic or test-positive COVID-19 infection in
HCWs.
• Significant adverse event: anosmia (or disturbance in sense of
smell).
Secondary outcomes
• Viral content of aerosol, when present (if intervention
administered to patients).
• Other adverse events: changes in microbiome in oral cavity,
nasal cavity, oro- or nasopharynx.
• Other adverse events: allergy, irritation/burning of nasal, oral
or oropharyngeal mucosa (e.g. erosions, ulcers, bleeding),
long-term staining of mucous membranes or teeth, accidental
ingestion.
Search methods for identification of studies
The Cochrane ENT and Cochrane Oral Health Information
Specialists conducted systematic searches for all human studies.
There were  no language, publication year or publication status
restrictions. We contacted original authors for clarification and
further data when trial reports were  unclear and arranged
translations of papers where possible. The date of the search was
1 June 2020.
Electronic searches
The Information Specialist searched:
• the Cochrane Central Register of Controlled Trials (CENTRAL
2020, Issue 6) (searched via the Cochrane Register of Studies);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)
(1946 to 1 June 2020);
• Ovid EMBASE (1974 to 1 June 2020);
• World Health Organization (WHO) COVID-19 Global literature
on coronavirus disease https://search.bvsalud.org/global-
literature-on-novel-coronavirus-2019-ncov (searched to 1 June
2020);
• Cochrane COVID-19 Study Register https://
covid-19.cochrane.org/ (search via the Cochrane Register of
Studies to 1 June 2020).
The Information Specialist modelled subject strategies for
databases on the search strategy designed for Ovid MEDLINE.
Search strategies for major databases including CENTRAL are
provided in Appendix 1.
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Searching other resources
We did  not perform a separate search for adverse eFects. We
planned to consider adverse eFects described in the included
studies only.
We did not perform a separate search for pre-print publications.
We planned to identify and report as awaiting assessment any we
identified from the sources above that met our inclusion criteria
but we would not extract the data until their publication in a peer-
reviewed journal.
We planned to make eForts to identify full-text papers regardless
of language of publication and to endeavour to seek help with
translation; however, we did not plan to hold up the rapid review
process. Any papers that we were unable to source quickly or
unable to get translated would be listed as awaiting assessment.
Data collection and analysis
Selection of studies
AMG, HW (and others) performed screening using Covidence.
Two review authors independently screened all titles and abstracts
identified through the searching process Discrepancies were
discussed and, where necessary, a third review author was
included. Where uncertainties remained, we retrieved the full text
for clarification. Two review authors again screened the full text of
potentially relevant articles, independently.
We documented and outlined in the final report all decisions
regarding exclusion of studies, taken during screening, with a list of
excluded studies.
Data extraction and management
We planned that AMG, HW (and others) would perform data
extraction using a predefined data extraction form (Word/Excel).
Data were limited to a minimal set of required data items following
input from content experts and methodologists.
A single review author would undertake data extraction and a
second review author would check the completeness/accuracy of
the data extraction. Discrepancies would be discussed and taken to
a third review author as required.
We planned to contact study authors for missing outcome data, or
where there were conflicting data reported across multiple sources
for a single study.
Assessment of risk of bias in included studies
We planned to undertake 'Risk of bias' assessment at the same time
as data extraction. We planned to use the Cochrane RCT 'Risk of
bias' tool and the ROBINS-I tool for non-randomised studies. We
planned to exclude studies judged to be at critical risk of bias from
analysis.
As for data extraction, all judgements were to be checked by a
second review author. Discrepancies would be discussed and taken
to a third review author as required.
Measures of treatment e=ect
We planned to present dichotomous data as risk ratios (RR) with
corresponding 95% confidence intervals (CIs). However, if we
identified case-control studies relevant to the review questions, we
would have considered the use of odds ratio as the appropriate
estimate of eFect.
We planned to present continuous data as mean diFerence (MD)
with corresponding 95% CIs. Where necessary, we would have
converted outcome data to the same unit of measurement.
Where data were extracted from non-RCTs, we planned to use
adjusted eFects where available. If multiple adjusted eFects were
reported, then we would have chosen the one judged to minimise
the risk of bias due to confounding.
Unit of analysis issues
The unit of analysis was the participant. Any cluster-RCTs would
need to have analysed results taking account of the clustering
present in the data, otherwise we would have used the methods
outlined in Section 16.3.4 of the Cochrane Handbook for Systematic
Reviews of Interventions in order to perform an approximately
correct analysis (Higgins 2011). We planned to include studies with
multiple treatment arms as appropriate, ensuring that there was no
double counting of patients in any meta-analysis.
Dealing with missing data
We planned to contact study authors for missing outcome data.
Where appropriate, we would have used the methods outlined
in Section 7.7.3 of the Cochrane Handbook for Systematic Reviews
of Interventions in order to estimate missing standard deviations
(Higgins 2011). We would not have used any further statistical
methods or carried out any further imputation to account for
missing data.
Assessment of heterogeneity
We planned to assess statistical heterogeneity initially through
inspection of forest plots. We would use the Chi2 for heterogeneity,
with P = 0.10, to indicate substantial heterogeneity (acknowledging
that this has low power if there is a small sample size or few studies).
We also planned to use the I2 statistic, following the interpretation
recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (0% to 40% might not be important; 30% to
60% may represent moderate heterogeneity; 50% to 90% may
represent substantial heterogeneity; 75% to 100% considerable
heterogeneity) (Handbook 2019). We would be cautious in
interpreting the I2 value, as this may be uncertain when there are
few studies.
We planned to explore potential sources of heterogeneity among
study results. Sources may include: clinical setting and clinical
procedure.
Assessment of reporting biases
Where there were 10 or more studies in a meta-analysis, we planned
to assess possible publication bias by visually inspecting a funnel
plot for asymmetry.
Data synthesis
We planned to make a judgement regarding the clinical and
methodological heterogeneity; only where there was deemed to
be reasonable homogeneity across studies would we consider
statistical pooling of data. If appropriate, we would have conducted
Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with
suspected or confirmed COVID-19 infection (Review)









Cochrane Database of Systematic Reviews
statistical pooling of data from RCTs, followed by data from non-
RCTs. We would not have undertaken pooling across diFerent types
of study designs.
We planned to use a random-eFects model.
Lastly, we planned to undertake a narrative synthesis,
encompassing findings from both RCT and non-RCT studies.
Subgroup analysis and investigation of heterogeneity
Where data were available, we planned to conduct subgroup
analyses, where possible, according to clinical procedure (AGP
versus non-AGP) and clinical setting (e.g. inpatient, outpatient,
dental, ENT).
Sensitivity analysis
We planned to undertake sensitivity analysis excluding studies at
high risk of bias.
Summary of findings and assessment of the certainty of the
evidence
We planned to use the GRADE approach and present 'Summary of
findings' tables for all comparisons and all outcomes.
R E S U L T S
Description of studies
Results of the search
The searches retrieved a total of 335  references. This reduced
to 240  aKer the removal of duplicates.  We screened the titles
and abstracts of the remaining 240  references. We discarded
206  references and assessed 34  full-text articles. We identified
four additional duplicates, which we discarded. We excluded
27  references with reasons recorded in the review (see Excluded
studies).
We did not identify any completed studies that met the inclusion
criteria for  this review. We identified three ongoing studies
(NCT04408183; NOCOVID (NCT04337918); PIIPPI (NCT04364802)).
See Characteristics of ongoing studies for further details.
The PRISMA diagram in  Figure 1  shows our study search and
selection process.
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Figure 1.   Process for siGing search results and selecting studies for inclusion.
 
Included studies
We did not include any studies.
Excluded studies
We excluded 28 papers aKer reviewing the full text. Further details
for the reasons for exclusion can be found in the Characteristics of
excluded studies table.
These are the main reasons for exclusion:
We excluded seven references that were narrative review articles,
which did not report any data of relevance to this review (Carrouel
2020; Dexter 2020; Ham 2020; Hamid 2020; Henwood 2020;
Leboulanger 2020; Parhar 2020).
We also excluded four references as they were letters to the editor
of a journal, providing a comment rather than reporting on a study
(Challacombe 2020; LoKus 2020; Mady 2020; Maguire 2020).
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We excluded 15  studies  as the intervention was used in
an incorrect population - the trial considered the use
of nasal sprays and gargles  to treat individuals who
have the virus, rather than as prophylaxis to prevent
transmission of the virus (ACTRN12620000470998p; AMPoL
(NCT04409873); BBCovid (NCT04352959); ChiCTR2000030539;
ELVIS-COVID-19 (NCT04382131); GARGLES (NCT04341688);
GARGLESb (NCT04410159) KILLER (NCT04371965); KONS-COVID-19
(NCT04357990); NCT04344236; NCT04347954; NCT04382040;
NCT04347538; PICO (ISRCTN13447477); SINUS WASH
(NCT04393792)).
Finally, we excluded one study as it was conducted in an
incorrect population - although participants were infected with a
coronavirus, this was not COVID-19 (Ramalingam 2020).
Ongoing studies
We identified three ongoing studies, aiming to enrol 675
participants, which may provide data for future versions of this
review. It should be noted that not all of these studies have
begun recruiting participants, therefore they should be regarded as
'planned or ongoing studies'.
Two of the studies are reported to be RCTs (NCT04408183;
NOCOVID (NCT04337918)), and the third study is reported as a
non-randomised intervention study (PIIPPI (NCT04364802)). They
evaluate the eFectiveness of diFerent interventions, including
povidone iodine (as a nasal spray and gargle), nitric oxide (as a
gargle, nasopharyngeal rinse and nasal spray) and GLS-1200 oral
spray (the constituent of this spray is unclear and may not be
antimicrobial in nature). 
The studies all consider the incidence of COVID-19 as an outcome,
and some consider the severity of the disease. Adverse events are
considered by only one trial, although the remaining trials do look
at tolerability of use for the intervention.
Risk of bias in included studies
No studies are included in the review.
E=ects of interventions
See: Summary of findings 1 Nasal sprays and gargles compared
to no intervention for protecting healthcare workers when treating
patients with suspected COVID-19
No studies are included in the review. See Summary of findings 1.
D I S C U S S I O N
Summary of main results
We identified no studies for inclusion in this review. This is
not surprising given the relatively recent emergence of COVID-19
infection. It is, however, good that the question posed in this review
is being addressed by ongoing studies.
Overall completeness and applicability of evidence
We are concerned that only one of the ongoing studies specifically
states that it will consider adverse events. A number of specific
issues are problematic and some may remain so even if they are
addressed in the studies.
Anosmia
Anosmia may occur as an adverse eFect of the intervention, rather
than a consequence of the COVID-19 infection. Since temporary or
permanent anosmia are now  recognised features of the disease
(Menni 2020),  any small increase in prevalence occurring as an
adverse eFect will be diFicult to identify without data from large
numbers of trial participants. Moreover, trials must have been
conducted over the required time period if both temporary and
permanent anosmia are to be detected.
Microbiome changes and antimicrobial resistance
Changes to the oral and nasal  microbiota  induced by the
application of antimicrobial substances into the oral and nasal
cavities and the nasopharynx may have adverse consequences for
participants. It is very diFicult to be certain about the severity and
likelihood of these adverse consequences, in particular in respect of
nasal irrigation, which is much less commonly undertaken than oral
irrigation. Good data are unlikely to come from any RCTs or other
trials included in this review.
However, some indication of the likely frequency and
severity of adverse events due to changes in the oral
and nasal  microbiota  can be obtained from the current
use of similar formulations. The use of oral rinses
containing broad-spectrum  antimicrobial compounds  such
as the  bisbiguanide  antiseptic  chlorhexidine  is common
globally.  Adverse eFects specifically  associated  with changes
in the composition  of the oral or pharyngeal  microbiota  have
generally not been reported (Tartaglia 2019).
Likewise,  microbiome-associated adverse events have
generally  not been reported in clinical methicillin-resistant
Staphylococcus aureus (MRSA) decolonisation protocols involving
the application of mupirocin (a broad-spectrum topical antibiotic)
to the inner surface of the nostrils several times daily. Thus, in short-
term applications, both types of adverse events can be considered
to be very rare and most likely mild.
There is a potential risk of microbial adaptation to both mupirocin
and chlorhexidine and there have been reports of correlations
between biocide and antibiotic susceptibility in clinical isolates.
As with the use of these compounds in MRSA decolonisation, the
balance of risk (that may be diFicult to quantify) versus benefit
must be considered.
Duration of treatment
The duration of treatment in the ongoing trials is relatively short, as
is the follow-up period. If interventions are shown to be of benefit in
reducing viral transmission then it is likely that healthcare workers
would need to use them  for extended periods, and at  least for
as long as  they interact with individuals who are known to have
COVID-19. An extended period of use may result in an increase in
adverse events, or reduced tolerability of the interventions, which
may not be evident from short-term studies. 
Balance of benefits versus harms
Very few interventions have large and dramatic eFect sizes. If
a positive treatment eFect is demonstrated when studies are
available for inclusion in this review, it may not be large. In these
circumstances in particular it may be a challenge to weigh up the
benefits against the harms if the latter are of uncertain frequency
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and severity. However, in the context of a global pandemic, even
those interventions with a modest benefit have the potential to
reduce the overall burden of disease considerably.
Quality of the evidence
No studies are included in the review.
Potential biases in the review process
Given the recent emergence of COVID-19 infection, we aimed to
design a protocol that would be inclusive, to encompass as much
relevant information as possible.
The search strategy was designed and run by qualified Cochrane
Information Specialists so any bias here should be minimal. The
search was not limited to the English language. It is possible that
suitable studies have been carried out and the results published
elsewhere in another language; however, we feel that this is
unlikely, as all applicable studies are likely to have been registered
with one of the central trial registries.
All studies that we discarded during our search and selection
process were rejected based on a lack of relevant data (e.g. they
were letter to the editor of a journal, or narrative review articles) or
because they did not address the relevant population.
Agreements and disagreements with other studies or
reviews
We are not aware of any other published reviews that address
the use of antimicrobial mouthwashes and nasal sprays to protect
healthcare workers when treating patients with suspected or
confirmed COVID-19 infection. We await the publication of the
ongoing trials with interest.
Evidence for activity of specific antimicrobials against SARS-
CoV-2 is still developing. However, povidone iodine mouthwash
has previously been shown to have antiviral activity against
coronaviruses, and new data suggest that it may also be eFective
against SARS-CoV-2 in particular (Bidra 2020).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
No studies are included in this review, therefore we are unable to
ascertain the relative benefits and harms of the use of antimicrobial
mouthwashes and nasal sprays by healthcare workers who are
treating patients with COVID-19.
Implications for research
It is promising that a small number of ongoing studies were
identified by the literature searches for  this review. However,
we note that some important issues may not be addressed by
the trials that are currently ongoing –  in particular the adverse
eFects from both short- and longer-term use of the interventions.
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washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a).
BBCovid (NCT04352959) Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020b). 
Carrouel 2020 Review article, no relevant data. 
Challacombe 2020 Letter to the editor, no relevant data.
ChiCTR2000030539 Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a). 
Dexter 2020 Review article, no relevant data. 
ELVIS-COVID-19
(NCT04382131)
Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a).
GARGLES (NCT04341688) Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
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Study Reason for exclusion
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a). 
GARGLESb (NCT04410159) Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a).
Ham 2020 Review article, no relevant data. 
Hamid 2020 Review article, no relevant data. 
Henwood 2020 Review article, no relevant data. 
KILLER (NCT04371965) Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19




Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a). 
Leboulanger 2020 Review article, no relevant data. 
Loftus 2020 Letter to the editor, no relevant data. 
Mady 2020 Letter to the editor, no relevant data. 
Maguire 2020 Letter to the editor, no relevant data. 
NCT04344236 Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a). 
NCT04347538 Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a).
NCT04347954 Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a). 
NCT04382040 Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
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Study Reason for exclusion
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a).
Parhar 2020 Review article, no relevant data. 
PICO (ISRCTN13447477) Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a).
Ramalingam 2020 Incorrect population. Although participants were infected with a coronavirus, this was not COV-
ID-19.
SINUS WASH (NCT04393792) Incorrect population. This trial considers the use of nasal sprays/gargles by individuals who are
diagnosed with COVID-19, and is relevant for another review in this suite (Antimicrobial mouth-
washes (gargling) and nasal sprays administered to patients with suspected or confirmed COVID-19
infection to improve patient outcomes and to protect healthcare workers treating them; Burton
2020a).
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name 'GLS-1200 topical nasal spray to prevent SARS-CoV-2 infection (COVID-19) in health care personnel'
Methods 2-arm, parallel-group RCT
Participants Adult healthcare professionals
Inclusion criteria:
• Aged 18 or over
• Able to provide informed consent
• Able and willing to comply with study procedures
• Adult healthcare professional
Exclusion criteria:
• Known allergy to quinine, quinidine or mefloquine
• Confirmed prior positive test for SARS-CoV-2
• Treatment within the past 2 weeks with chloroquine, hydroxychloroquine or remdesivir
Planned sample size: 225 participants
Interventions Intervention group:
• 1 mL of GLS-1200 per nostril, 3 times daily via atomiser (duration not stated)
Comparator group:
• 1 mL of 0.9% saline per nostril, 3 times daily via atomiser (duration not stated)
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• Number of GLS-1200 topical nasal spray adverse events; time frame: 4 weeks
• Incidence of SARS-CoV-2 infection, confirmed by PCR; time frame: 4 weeks
Secondary outcomes:
• Symptom score of documented SARS-CoV-2 infection; time frame: 4 weeks
Starting date May 2020
Contact information Email: jmaslow@geneonels-us.com; cremigio@geneonels-us.com
Notes Trial registered in USA




Study name 'Multi-center, randomized, controlled, phase II clinical efficacy study evaluating nitric oxide releas-
ing solution treatment for the prevention and treatment of COVID-19 in healthcare workers and in-
dividuals at risk of infection' 
Methods Multicentre, parallel-group, single-blind randomised controlled trial
Participants Healthcare workers and individuals who are negative for COVID-19 during screening, aged 19 years
and over
Inclusion criteria:
• Capacity to consent to participation
• 19 years of age or older
• English speaking
• Willing to use adequate contraception for the duration of the trial
• Symptom free at screening/baseline
• Working/living in contact with COVID-19 infected patients, or scheduled to work in a setting with
high likelihood of exposure to COVID-19 infected patients
Exclusion criteria:
• Prior tracheostomy
• Concomitant treatment of respiratory support (involving any form of oxygen therapy)
• Any clinical contraindications, as judged by the attending physician
• Any symptoms consistent with COVID-19
• Pregnancy
• Mentally or neurologically disabled participants who are not considered fit to consent to the study
• Prior COVID-19 infection
Planned sample size: 200 participants
Interventions Intervention group:
• Daily self-administration of nitric oxide gargle every morning, nitric oxide nasopharyngeal irriga-
tion every evening and nitric oxide nasal spray up to 5 times per day, for 14 days
Comparator group:
• No intervention
Use of additional interventions in both groups:
NOCOVID (NCT04337918) 
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• All participants will receive standard institutional precautions
Outcomes Primary outcome:
• Proportion of healthcare workers with either positive COVID-19 or presentation of clinical symp-
toms (fatigue with either fever (> 37.2ºC) and/or a persistent cough); time frame: 21 days following
randomisation
Secondary outcomes:
• Proportion of participants requiring hospitalisation for COVID-19/flu-like symptoms and/or need-
ing oxygen therapy, BIPAP/CPAP, intubation and mechanical ventilation following enrolment;
time frame: 21 days following randomisation
• Tolerability of nitric oxide releasing solution (NORS) treatment; time frame: 21 days following ran-
domisation
Starting date 8 May 2020
Contact information Chris Miller
Email: chris@sanotize.com
Notes Primarily a prevention study, but has a second arm to the trial that considers the use of the same
interventions in individuals who have COVID-19 (relevant for another review in this suite). 
Trial registered in the USA




Study name 'COVID-19: povidone-iodine intranasal prophylaxis in front-line healthcare personnel and inpa-
tients (PIIPPI)'
Methods Non-randomised clinical trial
Participants Frontline healthcare workers who are negative for COVID-19 or hospital inpatients (who have
a hospitalisation of more than 7 days, or who are set to undergo a significant surgical procedure),
aged 18 to 99 years
Inclusion criteria:
• Healthcare worker OR patient with expected hospital stay of 7+ days OR patient admitted for ma-
jor surgery
• COVID-19 negative by nasal swab test
• Asymptomatic for COVID-19
• Able to consent to participation
Exclusion criteria:
• Positive for COVID-19 by nasal swab
• Symptomatic for COVID-19
• Unable to consent
Planned sample size: 250 participants
Interventions Intervention group:
PIIPPI (NCT04364802) 
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• For healthcare workers: povidone-iodine nasal spray and gargle (10% diluted 1:30) will be used at
the beginning of their shiK, in the middle and at the end of their shiK
• For hospital inpatients: povidone-iodine nasal spray and gargle (10% diluted 1:30) for patient par-
ticipants to use shortly after admission or pre-operatively (no further details provided)
Comparator group:
• No intervention
Use of additional interventions for both study groups:
• Standard PPE and a pre- and post-study test for COVID-19
Outcomes Primary outcomes:
• Percentage of healthcare workers testing positive for COVID-19; time frame: 3 weeks
• Percentage of patients testing positive for COVID-19; time frame: 2 weeks
Secondary outcomes:
• PVP-I ease of use; time frame: 3 weeks
• PVP-I comfort; time frame: 3 weeks
• Adherence to treatment protocol; time frame: 3 weeks
Starting date May 2020
Contact information Alexandra Kejner
Email: alexandra.kejner@uky.edu
Notes Trial registered in USA
Estimated completion date: May 2021
PIIPPI (NCT04364802)  (Continued)
BIPAP: bilevel positive airway pressure; COVID-19 coronavirus disease 2019; CPAP: continuous positive airway pressure; PCR: polymerase
chain reaction; PPE: personal protective equipment; PVP-I povidone iodine; RCT: randomised controlled trial; SARS-CoV-2: severe acute
respiratory syndrome coronavirus 2
 
 
A P P E N D I C E S
Appendix 1. Search strategies
 
CENTRAL Ovid MEDLINE Ovid Embase
1 ("2019 nCoV" or 2019nCoV or "COVID 19" or
COVID19 or "new coronavirus"       or "novel
coronavirus" or "novel corona virus" or "SARS
CoV-2" or "2019-        novel CoV" or ncov19 or
ncov-19) AND CENTRAL:TARGET
2 (Wuhan and (coronavirus or "corona virus"))
AND CENTRAL:TARGET
3 ((coronavirus near3 2019) or ("corona virus"
near3 2019)) AND      CENTRAL:TARGET  
1 ("2019 nCoV" or 2019nCoV or "COVID 19" or COV-
ID19 or "new coronavirus"       or "novel coronavirus"
or "novel corona virus" or "SARS CoV-2" or "2019-       
novel CoV" or ncov19 or ncov-19).ab,ti.
2 (Wuhan and (coronavirus or "corona virus")).ab,ti.
3 ((coronavirus or "corona virus") adj3 "2019").ab,ti.
4 (wuhan adj2 (disease or virus)).ab,ti.
5 ("LAMP assay" or "COVID-19" or "COVID-19 drug
treatment" or "COVID-19          diagnostic testing"
1. ("2019 nCoV" or
2019nCoV or "COVID
19" or COVID19 or "new
coronavirus" or "novel
coronavirus" or "novel
corona virus" or "SARS
CoV-2" or "2019-        nov-
el CoV" or ncov19 or
ncov-19).ab,ti.       
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4 ((wuhan near2 disease) or (wuhan near2 virus))
AND CENTRAL:TARGET
5 ("LAMP assay" or "COVID-19" or "COVID-19
drug treatment" or "COVID-19 diagnostic test-
ing" or "COVID-19 serotherapy" or "COVID-19
vaccine" or "severe acute respiratory syndrome
coronavirus 2" or "spike glycoprotein, COVID-19
virus") AND CENTRAL:TARGET  
6 #1 OR #2 OR #3 OR #4 OR #5         
7 MESH DESCRIPTOR Mouthwashes EXPLODE
ALL AND CENTRAL:TARGET
8 MESH DESCRIPTOR Nasal Sprays EXPLODE ALL
AND   CENTRAL:TARGET  
9 MESH DESCRIPTOR Nasal Lavage EXPLODE ALL
AND CENTRAL:TARGET
10 (mouthwash* or gargl* or mouthrins*) AND
CENTRAL:TARGET    
11 (oral near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or           decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET  
12 (mouth near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or       decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET  
13 (nasal near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or        decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET  
14 (nose near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or         decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET  
15 (nasopharyngeal near3 (spray* or douch* or
irrigat* or lavag* or wash or rins* or deconta-
minat* or aerosol or mist or clean*)) AND CEN-
TRAL:TARGET
16 (larynx* near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or      decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
17 (pharynx* near3 (spray* or douch* or irrigat*
or lavag* or wash or rins* or   decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
18 (intranasal near3 (spray* or douch* or irrigat*
or lavag* or wash or rins* or decontaminat* or
aerosol or mist or clean*)) AND CENTRAL:TAR-
GET
or "COVID-19 serotherapy" or "COVID-19 vaccine"
or           "severe acute respiratory syndrome coron-
avirus 2" or "spike glycoprotein, COVID-19 virus").os.
6 1 or 2 or 3 or 4 or 5
7 exp Animals/
8 exp Humans/
9 7 not 8
10 (editorial or comment or letter or newspaper arti-
cle).pt.
11 9 or 10
12 6 not 11
13 exp Mouthwashes/
14 exp Nasal Sprays/
15 exp Nasal Lavage/
16 (mouthwash* or gargl* or mouthrins*).ab,ti.
17 ((oral or mouth or nasal or nose or nasopha-
ryngeal or larynx* or pharynx* or intranasal) adj3
(spray* or douch* or irrigat* or lavag* or wash






22 exp Anti-Infective Agents, Local/
23 exp Hydrogen Peroxide/
24 exp Carbamide Peroxide/
25 exp Triclosan/
26 exp Oils, volatile/











4. (wuhan adj2 (disease
or virus)).ab,ti.
5. ("LAMP assay" or
"COVID-19" or "COVID-19
drug treatment" or "COV-
ID-19 diagnostic testing"
or "COVID-19 serother-
apy" or "COVID-19 vac-
cine" or "severe acute
respiratory syndrome







10. (mouthwash* or gar-
gl* or mouthrins*).ab,ti.  
11. ((oral or mouth or
nasal or nose or na-
sopharyngeal or lar-
ynx* or pharynx* or in-
tranasal) adj3 (spray*
or douch* or irrigat*
or lavag* or wash or
rins* or decontaminat*
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19 MESH DESCRIPTOR Chlorhexidine EXPLODE
ALL AND CENTRAL:TARGET
20 MESH DESCRIPTOR Povidone-Iodine EX-
PLODE ALL AND          CENTRAL:TARGET
21 MESH DESCRIPTOR Cetylpyridinium EXPLODE
ALL AND            CENTRAL:TARGET
22 MESH DESCRIPTOR Hexetidine EXPLODE ALL
AND CENTRAL:TARGET
23 MESH DESCRIPTOR Anti-Infective Agents, Lo-
cal EXPLODE ALL AND    CENTRAL:TARGET
24 MESH DESCRIPTOR Hydrogen Peroxide EX-
PLODE ALL AND     CENTRAL:TARGET
25 MESH DESCRIPTOR Carbamide Peroxide EX-
PLODE ALL AND   CENTRAL:TARGET
26 MESH DESCRIPTOR Triclosan EXPLODE ALL
AND CENTRAL:TARGET
27 MESH DESCRIPTOR Oils, Volatile EXPLODE
ALL AND CENTRAL:TARGET
28 MESH DESCRIPTOR Plant Oils EXPLODE ALL
AND CENTRAL:TARGET
29 MESH DESCRIPTOR Menthol AND CEN-
TRAL:TARGET
30 MESH DESCRIPTOR Lavandula AND CEN-
TRAL:TARGET
31 MESH DESCRIPTOR Thymus Plant AND CEN-
TRAL:TARGET
32 MESH DESCRIPTOR Mentha piperita AND
CENTRAL:TARGET
33 MESH DESCRIPTOR Cinnamomum zeylan-
icum AND CENTRAL:TARGET
34 MESH DESCRIPTOR Muramidase AND CEN-
TRAL:TARGET
35 MESH DESCRIPTOR Lactoferrin AND CEN-
TRAL:TARGET
36 MESH DESCRIPTOR Glucose Oxidase AND
CENTRAL:TARGET
37 MESH DESCRIPTOR Lactoperoxidase AND
CENTRAL:TARGET
38 (povidone or chlorhexidine or CHX or PVP or
Polyvinylpyrrolidone or         Betadine* or Provi-
dine* or Disadine* or Isodine* or Pharmadine*
or         Alphadine* or Betaisodona or Tubulicid or





38 (povidone or chlorhexidine or CHX or PVP or
Polyvinylpyrrolidone or Betadine* or Providine* or
Disadine* or Isodine* or Pharmadine* or         Alpha-
dine* or Betaisodona or Tubulicid or Novalsan or Se-
bidin or MK-412A or MK412A).ab,ti.
39 (Chlorhexamed or Corsodyl or Curasept or Dy-
na-Hex or Eludril or Gibitan or Hexidine or Hibiclens
or Hibident or Hibiscrub or Hibisol or Hibitane or
Peridex or avagard).ab,ti.
40 (Hexadecylpyridinium or Cetylpyridium or
Biosept or Ceepryn or Cetamium or Catamium or
Sterogenol or Dobendan or Merocets or Pristacin or
Pyrisept or Angifonil or Cetylyre).ab,ti.
41 (Vagi-Hex or Vagi Hex or VagiHex or Oraldene or
Hexigel or Steri-sol or Steri sol or Hextril or Oraldine
or Oralspray or Hexoral or Bactidol or Elsix or Duranil
or Doreperol or Hexetidine).ab,ti.
42 (Hydrogen Peroxide or H2O2 or Hydroperoxide or
Superoxol or Oxydol or Perhydrol or Urea Peroxide
or Perhydrol Urea).ab,ti.
43 (Methyl salicylate or methylsalicylate or Rheuma-
bal or Metsal Liniment or Hewedolor or Linsal).ab,ti.
44 (Tricolsan or Hydroxydiphenyl or
trichlorodiphenyl or Clearasil or Cliniclean or Irgasan
or Trisan or Oxy Skin Wash or pHisoHex or Sapoderm
or Tersaseptic or Aquasept or Ster-Zac or Manusept
or Microshield).ab,ti.
45 ((Spray* or douch* or irrigat* or rins* or wash*
or lavag* or intranasal* or topical) adj3 (antimicro-
bial or anti-microbial or disinfect* or antisept* or an-
ti-         infect*)).ab,ti.
46 ("essential oil$" or "plant oil$" or menthol or
menthyl or (mint adj2 oil$) or   lavender or thyme or
peppermint or "mentha piperita" or eugenol o euca-
lyptus or "blue gum$" or cajeput or clove or cinna-
mon).ab,ti.
47 (muramidase or lysozyme$ or leftose or lactofer-
rin or lactotransferrin or "glucose oxidase" or lac-
toperoxidase or "saliva substitute").ab,ti.
48 (Listerine or Biotene).ab,ti.
49 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
or 22 or 23 or 24 or 25 or 26      or 27 or 28 or 29 or 30
or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or
           40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48












chlorhexidine or CHX or
PVP or Polyvinylpyrroli-
done or Betadine* or
Providine* or Disadine*
or Isodine* or Pharma-
dine* or         Alphadine*
or Betaisodona or Tubu-
licid or Novalsan or Se-
bidin or MK-412A or
MK412A).ab,ti.           
32. (Chlorhexamed or
Corsodyl or Curasept or
Dyna-Hex or Eludril or
Gibitan or Hexidine or Hi-
biclens or Hibident or Hi-
biscrub or Hibisol or Hi-
bitane or Peridex or ava-
gard).ab,ti.      
33. (Hexadecylpyridini-
um or Cetylpyridium or
Biosept or Ceepryn or
Cetamium or Catami-
um or Sterogenol or
Dobendan or Merocets
or Pristacin or Pyrisept
or           Angifonil or Cety-
lyre).ab,ti.    
34. (Vagi-Hex or Vagi Hex
or VagiHex or Oraldene
or Hexigel or Steri-sol
or Steri sol or Hextril or
Oraldine or Oralspray or
Hexoral or Bactidol or El-
six or Duranil or Doreper-
ol or Hexetidine).ab,ti.     
35. (Hydrogen Peroxide
or H2O2 or Hydroperox-
ide or Superoxol or Oxy-
dol or             Perhydrol or
  (Continued)
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39 (Chlorhexamed or Corsodyl or Curasept or
Dyna-Hex or Eludril or Gibitan or Hexidine or
Hibiclens or Hibident or Hibiscrub or Hibisol
or Hibitane or Peridex or avagard) AND CEN-
TRAL:TARGET
40 (Hexadecylpyridinium or Cetylpyridium or
Biosept or Ceepryn or Cetamium or       Catami-
um or Sterogenol or Dobendan or Merocets or
Pristacin or Pyrisept or           Angifonil or Cety-
lyre) AND CENTRAL:TARGET
41 (Vagi-Hex or Vagi Hex or VagiHex or Oraldene
or Hexigel or Steri-sol or Steri sol or Hextril or
Oraldine or Oralspray or Hexoral or Bactidol or
Elsix or      Duranil or Doreperol or Hexetidine)
AND CENTRAL:TARGET       
42 (Hydrogen Peroxide or H2O2 or Hydroperox-
ide or Superoxol or Oxydol or Perhydrol or Urea
Peroxide or Perhydrol Urea) AND CENTRAL:TAR-
GET  
43 (Methyl salicylate or methylsalicylate or
Rheumabal or Metsal Liniment or Hewedolor or
Linsal) AND CENTRAL:TARGET
44 (Tricolsan or Hydroxydiphenyl or
trichlorodiphenyl or Clearasil or Cliniclean or
Irgasan or Trisan or Oxy Skin Wash or pHiso-
Hex or Sapoderm or Tersaseptic or Aquasept or
Ster-Zac or Manusept or Microshield) AND CEN-
TRAL:TARGET
45 ((spray* or douch* or irrigat* or rins* or wash*
or lavag* or intranasal* or    topical) and (antimi-
crobial or anti-microbial or disinfect* or anti-
sept* or anti-infect*)) AND CENTRAL:TARGET
46 ("essential oil*" or "plant oil*" or menthol
or menthyl or (mint near2 oil*) or lavender or
thyme or peppermint or "mentha piperita"
or eugenol or       eucalyptus or "blue gum*"
or cajeput or clove or cinnamon) AND    CEN-
TRAL:TARGET
47 (muramidase or lysozyme* or leftose or lacto-
ferrin or lactotransferrin or     "glucose oxidase"
or lactoperoxidase or "saliva substitute") AND
            CENTRAL:TARGET
48 (Listerine or Biotene) AND CENTRAL:TARGET
49 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
OR #14 OR #15 OR #16         OR #17 OR #18 OR #19
OR #20 OR #21 OR #22 OR #23 OR #24 OR #25  
OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR
#32 OR #33 OR #34          OR #35 OR #36 OR #37
OR #38 OR #39 OR #40 OR #41 OR #42 OR #43     
OR #44 OR #45 OR #46 OR #47 OR #48
50 #49 AND #6   




Rheumabal or Metsal Lin-
iment or Hewedolor or
Linsal).ab,ti.    
37. ((spray* or douch* or
irrigat* or rins* or wash*
or lavag* or intranasal*
or topical) adj3 (antimi-
crobial or anti-micro-
bial or disinfect* or anti-
sept* or anti-         infec-
t*)).ab,ti. 
38. (Tricolsan or Hy-
droxydiphenyl or
trichlorodiphenyl or
Clearasil or Cliniclean or
Irgasan or Trisan or Oxy
Skin Wash or pHisoHex or
Sapoderm or Tersaseptic
      or Aquasept or Ster-
Zac or Manusept or Mi-
croshield).ab,ti. 
39. ("essential oil$" or
"plant oil$" or menthol
or menthyl or (mint adj2
oil$) or   lavender or
thyme or peppermint
or "mentha piperita" or
eugenol or eucalyptus
or "blue gum$" or ca-




or lactoferrin or lacto-
transferrin o "glucose
oxidase" or lactoperox-
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  (Continued)
Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with
suspected or confirmed COVID-19 infection (Review)









Cochrane Database of Systematic Reviews
WHO COVID-19 Register Cochrane COVID-19 Register —
(tw:((oral or mouth or nasal or nose or nasopha-
ryngeal or larynx* or pharynx* or intranasal) ))
AND (tw:(spray* or douch* or irrigat* or lavag*
or wash or rins* or decontaminat* or aerosol or
mist or clean*))
(tw:((mouthwash* or gargl* or mouthrins*)))
(tw:((spray* or douch* or irrigat* or rins* or
wash* or lavag* or intranasal* or topical))) AND
(tw:((antimicrobial or anti-microbial or disin-
fect* or antisept* or anti-infect*)))
(povidone or chlorhexidine or CHX or PVP or
Polyvinylpyrrolidone or Betadine* or Providine*
or Disadine* or Isodine* or Pharmadine* or Al-
phadine* or Betaisodona or Tubulicid or Noval-
san or Sebidin or MK-412A or MK412A)
1 (mouthwash* or gargl* or mouthrins*)  AND IN-
REGISTER
2 (oral near3 (spray* or douch* or irrigat* or lavag* or
wash or rins* or decontaminat* or aerosol or mist or
clean*))  AND INREGISTER
3 (mouth near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or decontaminat* or aerosol
or mist or clean*))  AND INREGISTER
4 (nasal near3 (spray* or douch* or irrigat* or lavag*
or wash or rins* or decontaminat* or aerosol or mist
or clean*))  AND INREGISTER
5 (nose near3 (spray* or douch* or irrigat* or lavag*
or wash or rins* or decontaminat* or aerosol or mist
or clean*))  AND INREGISTER
6  (nasopharyngeal near3 (spray* or douch* or irri-
gat* or lavag* or wash or rins* or decontaminat* or
aerosol or mist or clean*))  AND INREGISTER
7 (larynx* near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or decontaminat* or aerosol
or mist or clean*))  AND INREGISTER
8 (pharynx* near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or   decontaminat* or aerosol
or mist or clean*))  AND INREGISTER           
9 (intranasal near3 (spray* or douch* or irrigat* or
lavag* or wash or rins* or decontaminat* or aerosol
or mist or clean*))  AND INREGISTER
10 (povidone or chlorhexidine or CHX or PVP or
Polyvinylpyrrolidone or Betadine* or Providine* or
Disadine* or Isodine* or Pharmadine* or Alphadine*
or Betaisodona or Tubulicid or Novalsan or Sebidin
or MK-412A or MK412A)  AND INREGISTER
11 (Chlorhexamed or Corsodyl or Curasept or Dy-
na-Hex or Eludril or Gibitan or Hexidine or Hibiclens
or Hibident or Hibiscrub or Hibisol or Hibitane or 
Peridex or avagard) AND INREGISTER
12 (Hexadecylpyridinium or Cetylpyridium or
Biosept or Ceepryn or Cetamium or Catamium or
Sterogenol or Dobendan or Merocets or Pristacin or
Pyrisept or Angifonil or Cetylyre) AND INREGISTER
13 (Vagi-Hex or Vagi Hex or VagiHex or Oraldene or
Hexigel or Steri-sol or Steri sol or Hextril or Oraldine
or Oralspray or Hexoral or Bactidol or Elsix or Duranil
or Doreperol or Hexetidine)  AND INREGISTER
14 (Hydrogen Peroxide or H2O2 or Hydroperoxide or
Superoxol or Oxydol or Perhydrol or Urea Peroxide
or Perhydrol Urea)  AND INREGISTER
— 
  (Continued)
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15 (Methyl salicylate or methylsalicylate or Rheuma-
bal or Metsal Liniment or  Hewedolor or Linsal)  AND
INREGISTER
16 (Tricolsan or Hydroxydiphenyl or
trichlorodiphenyl or Clearasil or Cliniclean or Irgasan
or Trisan or Oxy Skin Wash or pHisoHex or Sapo-
derm or Tersaseptic       or Aquasept or Ster-Zac or
Manusept or Microshield)  AND INREGISTER
17 ((Spray* or douch* or irrigat* or rins* or wash*
or lavag* or intranasal* or    topical) and (antimicro-
bial or anti-microbial or disinfect* or antisept* or an-
ti           infect*))  AND INREGISTER
18 ("essential oil*" or "plant oil*" or menthol or
menthyl or (mint near2 oil*) or  lavender or thyme or
peppermint or "mentha piperita" or eugenol or eu-
calyptus or "blue gum*" or cajeput or clove or cinna-
mon)  AND   INREGISTER
19 (muramidase or lysozyme* or leftose or lacto-
ferrin or lactotransferrin or "glucose oxidase" or
lactoperoxidase or "saliva substitute")  AND    IN-
REGISTER
20 (Listerine or Biotene) AND INREGISTER
21 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15
OR #16 OR #17 OR #18 OR #19 OR #20
  (Continued)
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